Ozonated Oil Emulsion for Seborrhea in Women (OOSE)
A Randomized, Double-Blind, Placebo-Controlled Trial of an Ozonated Oil-Based Emulsion With Biotin for Seborrhea Management: Chemical Characterization, Stability Profiling, and Clinical Efficacy in Adult Women
This study evaluates a new ozonated oil-based hair cream for women with oily scalp (seborrhea). The cream contains natural oils (moringa, wheat germ, olive, and chili extract) treated with ozone, plus biotin (vitamin B7).
66 women aged 18-40 years participated in this 6-week study. Participants were randomly assigned to receive either:
- The active cream (ozonated oils + biotin), OR
- A placebo cream (without active ingredients)
Neither the participants nor the researchers knew which cream was given (double-blind). Participants applied the cream to their scalp every evening for 6 weeks.
The main goal was to measure changes in scalp oil (sebum) production at Week 6 compared to baseline. Other outcomes included hair manageability, shine, and scalp comfort.
Results showed that the active cream significantly reduced scalp oil by 28% compared to 10% in the placebo group. The cream was well-tolerated with only mild side effects (scalp irritation in 6% of active group).
This study suggests that ozonated oil emulsion may be a safe and effective cosmetic option for managing oily scalp in women.
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Yksityiskohtainen kuvaus
BACKGROUND:
Seborrheic scalp conditions affect 3-5% of adults, causing excessive oiliness and social discomfort. Current treatments use synthetic surfactants that may damage hair and scalp barrier. Ozonated oils represent a "green chemistry" approach that modifies natural oils to create bioactive compounds with antimicrobial and sebum-regulating properties.
INTERVENTION:
The study product is a low oil-in-water emulsion containing:
- Ozonated oil blend (7%): Moringa oleifera, Triticum vulgare, Olea europaea, Capsicum annuum oleoresin
- Biotin (0.1%): Vitamin B7 for keratin synthesis
- Placebo: Identical base without ozonated oils and biotin
STUDY DESIGN:
Single-center, randomized, double-blind, placebo-controlled parallel-group trial conducted at Al-Manara University, Syria (February-May 2024).
PARTICIPANTS:
66 adult women (18-40 years) with objective sebum ≥200 μg/cm² and self-reported daily hair washing due to oily scalp. Female-only enrollment to minimize sex-based variability in sebum production.
PRIMARY ENDPOINT:
Percent change from baseline in sebumeter-measured scalp sebum content at Week 6.
SECONDARY ENDPOINTS:
Hair manageability, shine, scalp comfort (0-10 scales), and Investigator Global Assessment.
STATISTICAL ANALYSIS:
ANCOVA on Week 6 absolute values with baseline covariate, following FDA guidance on covariate adjustment. Sensitivity analyses included MMRM and per-protocol.
KEY FINDINGS:
Active treatment showed 28.5% sebum reduction vs. 9.8% placebo (difference:
-18.7%, 95% CI: -22.0 to -15.5, p<0.0001), exceeding the 15% clinically meaningful threshold. All secondary endpoints favored active treatment.
LIMITATIONS:
Single-center, female-only, 6-week duration. Generalizability to males and long-term safety require further study.
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskelupaikat
-
-
-
Aleppo, Syyria
- Clinical Research Unit, Syrian Scientific Society for Medicinal Herbs, Aleppo
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
- Aikuinen
Hyväksyy terveitä vapaaehtoisia
Kuvaus
Inclusion Criteria:
- Female sex (biological), ages 18-40 years
- Objective sebum measurement ≥200 µg/cm² at baseline (Sebumeter SM 815)
- Self-reported daily or near-daily hair washing due to oily scalp
- Willing to abstain from other hair treatments for 2-week washout and study duration
- Signed informed consent
Exclusion Criteria:
- Active scalp dermatoses (psoriasis, atopic dermatitis, tinea capitis) requiring medical treatment
- Known hypersensitivity to study ingredients or fragrance components
- Pregnancy, lactation, or planned pregnancy during study period
- Systemic medications affecting sebum production (isotretinoin, hormonal contraceptives initiated within 3 months, anti-androgens)
- Participation in other cosmetic or pharmaceutical trials within 30 days
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Nelinkertaistaa
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Ozonated oil-based cosmetic emulsion
Low oil-in-water emulsion containing ozonated natural oils (Moringa oleifera, Triticum vulgare, Olea europaea, Capsicum annuum oleoresin) plus biotin 0.1%.
Applied 5g to scalp evening, overnight, rinsed morning for 6 weeks.
|
Low oil-in-water emulsion containing ozonated natural oils (Moringa oleifera 3%, Triticum vulgare 1.95%, Olea europaea 2%, Capsicum annuum oleoresin 0.05%) plus biotin 0.1%.
Applied 5g to scalp evening, overnight, rinsed morning for 6 weeks.
Muut nimet:
|
|
Muut: Matched vehicle control
Identical base formulation with caprylic/capric triglyceride and isopropyl palmitate to match total oil phase (8%), rheology, and cosmetic elegance.
Same application protocol: 5g evening, overnight, 6 weeks.
|
Identical base formulation with caprylic/capric triglyceride 6% and isopropyl palmitate 2% to match total oil phase (8%), rheology, and cosmetic elegance.
Same application protocol: 5g evening, overnight, 6 weeks.
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Percent change from baseline in scalp sebum content measured by Sebumeter
Aikaikkuna: Baseline (Day 0) and Week 6
|
Objective measurement of scalp sebum production using Sebumeter SM 815 (Courage+Khazaka, Germany).
Three standardized sites (vertex, left and right parietal regions) measured and averaged.
Negative values indicate sebum reduction.
Pre-specified clinically meaningful threshold: 15% absolute reduction.
|
Baseline (Day 0) and Week 6
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Hair shine score (investigator-rated)
Aikaikkuna: Baseline, Week 2, Week 4, Week 6
|
Standardized 10-point scale via standardized lighting and photography.
Higher scores indicate improved shine.
|
Baseline, Week 2, Week 4, Week 6
|
|
Scalp comfort score (participant-reported)
Aikaikkuna: Baseline, Week 2, Week 4, Week 6
|
Standardized 10-point scale (1=severe discomfort, 10=complete comfort).
Higher scores indicate improved comfort.
|
Baseline, Week 2, Week 4, Week 6
|
|
Investigator Global Assessment success rate
Aikaikkuna: Week 6
|
5-point categorical scale dichotomized as success (clear/almost clear) versus failure (mild/moderate/severe).
Assessed in per-protocol population with complete Week 6 data.
|
Week 6
|
Muut tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Adverse event rate
Aikaikkuna: Throughout 6-week study period
|
Number and severity of adverse events assessed via standardized query, severity grading (mild/moderate/severe), and causality assessment.
|
Throughout 6-week study period
|
|
Scalp irritation score
Aikaikkuna: Week 2, Week 4, Week 6
|
Scalp irritation assessed at each visit via participant self-report with severity grading.
|
Week 2, Week 4, Week 6
|
|
Product adherence percentage
Aikaikkuna: Throughout 6-week study period
|
Compliance assessed via returned product weighing (expected use: 35 g/week) and electronic diary entries.
|
Throughout 6-week study period
|
|
Treatment compliance rate
Aikaikkuna: Throughout 6-week study period
|
Percentage of expected product use calculated from returned product weight.
Threshold: ≥80% compliance.
|
Throughout 6-week study period
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Opintojen puheenjohtaja: Hisham M Kasem, Prof., Syrian Scientific Society for Medicinal Herbs
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- SHAMNA-2024-008
- SSS-008-2024 (Rekisterin tunniste: Syrian Scientific Society for Medicinal Herbs (SHAMNA))
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
IPD-jaon aikakehys
IPD-jaon käyttöoikeuskriteerit
IPD-jakamista tukeva tietotyyppi
- STUDY_PROTOCOL
- MAHLA
- ANALYTIC_CODE
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .